FIELD: medicine.
SUBSTANCE: method for reducing the inter-patient variability of levodopa in blood plasma in a patient population with Parkinson's disease is proposed, including the administration of from 20 mg to 50 mg of fine particles of levodopa (FPD) in the drug, consisting of 90 wt. % of levodopa, 8 wt. % of dipalmitoylphosphatidylcholine (DPPC) and 2 wt. % of sodium chloride, where the powder particles have mass density values of less than 0.4 g/cm3, MMAD from 1 to 5 microns, MMGD from 1 micron to 30 microns, by inhalation, at which the coefficient of variation for the variability of the concentration of levodopa in the blood plasma in different patients in a period of time from 10 minutes to 120 minutes after inhalation is less than 50 %.
EFFECT: technical result consists in increasing the reliability of the scheme of therapeutic treatment of patients suffering from Parkinson's disease.
10 cl, 7 dwg, 8 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| LEVODOPA FORMULATIONS FOR RAPID RELIEF OF PARKINSON'S DISEASE | 2013 |
|
RU2685718C2 |
| RAPID REDUCTION OF MOTOR FLUCTUATIONS ACCOMPANYING PARKINSON'S DISEASE | 2014 |
|
RU2698330C2 |
| COMPOSITIONS FOR CONTINUOUS CONTROL OF DOPA-DECARBOXYLASE INHIBITORS | 2010 |
|
RU2559083C9 |
| COMPOSITIONS FOR CONTINUOUS ADMINISTRATION OF DOPA-DECARBOXYLASE INHIBITORS | 2010 |
|
RU2678839C2 |
| METHOD FOR TREATMENT OF PARKINSON'S DISEASE | 2014 |
|
RU2677278C2 |
| ULTRA LOW DENSITY INHALATION POWDERS | 2013 |
|
RU2670987C2 |
| INTRODUCTION MODE FOR NITROCATECHOLS | 2011 |
|
RU2639131C2 |
| PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF LEVODOPA PRODRUG AND METHODS OF USING | 2010 |
|
RU2537137C2 |
| METHODS OF TREATING ENDOBRONCHIAL DISEASES | 2005 |
|
RU2389477C2 |
| PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE, LEVODOPA AND CARBIDOPA WITH IMPROVED BIOAVAILABILITY | 2009 |
|
RU2485947C2 |
